Roskilde March 20. 2021

Apillet ApS has secured the financing of the prototype and industrial master formula development of APIVAULT, Apillets novel gastro-resistant enteric encapsulation technology. The project paves the way to preclinical testing of the APIVAULT technology.

The financing is in the form of an angel investment. Apillet is actively looking for additional investments or pharma collaboration for funding the preclinical and clinical development of APIVAULT.